WO2022239605A1 - Agent virucide - Google Patents

Agent virucide Download PDF

Info

Publication number
WO2022239605A1
WO2022239605A1 PCT/JP2022/018024 JP2022018024W WO2022239605A1 WO 2022239605 A1 WO2022239605 A1 WO 2022239605A1 JP 2022018024 W JP2022018024 W JP 2022018024W WO 2022239605 A1 WO2022239605 A1 WO 2022239605A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
virucidal
virus
agent
adjuster
Prior art date
Application number
PCT/JP2022/018024
Other languages
English (en)
Japanese (ja)
Inventor
泰介 進藤
大介 笈川
Original Assignee
グラフトン株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラフトン株式会社 filed Critical グラフトン株式会社
Priority to JP2023520939A priority Critical patent/JPWO2022239605A1/ja
Publication of WO2022239605A1 publication Critical patent/WO2022239605A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a virucidal agent containing a component having a virucidal action and a specific acidic compound as a pH adjuster.
  • a known disinfectant whose main ingredient is alcohol is used to disinfect hands and instruments.
  • the disinfectant loses its effectiveness in inactivating the virus as the alcohol evaporates.
  • some of the quaternary ammonium salt-based and double-sided surfactant-based antiviral agents corrode metals, and while they are suitable as detergents, some are unsuitable for use in various applications. .
  • nanomaterial metal catalysts are widely used as virus-inactivating materials.
  • the metal catalyst is nano-sized, there is concern about its effects on living organisms (especially lungs).
  • the metal catalyst may peel or separate from the substrate surface depending on the environment in which it is used.
  • Patent Document 1 discloses a water-soluble metasilicate (especially sodium metasilicate), or a water-soluble metasilicate and an alkylpolyaminoethylglycine salt and/or an alkyldiaminoethylene lycine salt as a fungicide.
  • a virucidal agent comprising: Patent document 1 reports that the virucidal agent has a high inactivating effect against enveloped and non-enveloped viruses.
  • Non-Patent Document 1 discloses inactivation of nuclear polyhedrosis virus and cytoplasmic polyhedrosis virus.
  • Non-Patent Document 2 discloses inactivation of avian influenza virus.
  • Non-Patent Document 3 discloses inactivating the SARS-CoV-2 virus.
  • Non-Patent Document 1 and Non-Patent Document 2 an aqueous solution saturated with hydrated lime (pH ⁇ 12) is used, and the virucidal agent thereof is strongly basic.
  • Non-Patent Document 3 verifies the virus inactivation effect at pH ⁇ 12.
  • the present invention has been made in view of the above problems, and provides a virucidal agent that has stable properties, has an effect of inactivating viruses, and is less harmful to humans.
  • the task was to
  • a virucidal agent containing a component having a virucidal action and a pH adjuster comprises at least one selected from the group consisting of silicic acid, silicic acid salts, silicic acid hydrates, sodium hydroxide, calcium hydroxide, and potassium hydroxide
  • the pH adjuster contains an aldehyde group, a benzyl group, a benzal group, a vinyl group, an allyl group, an ethylene group, a methyl group, a cetyl group, an alkoxy group, a methoxy group, an ethyl group, a propyl group, a butyl group, a pyridyl group, and an amyl group.
  • a virucidal agent characterized in that it is an acidic compound or a combination of at least one acidic compound and a neutral compound thereof, and the pH of said virucidal agent is less than 12.
  • the pH adjuster is at least one acidic compound selected from the group consisting of acidic compounds having a carboxyl group and a hydroxyl group, acidic compounds having a sulfo group, amino acids, and salts thereof, or at least The disinfectant according to (1) or (2), characterized in that it is a combination of one acidic compound and a nonionic surfactant or zwitterionic surfactant having pH fine-tuning action and/or penetrating action. viral agent.
  • the pH adjuster is an amino acid having only hydrogen atoms in the side chain, an amino acid having a group composed of carbon atoms and hydrogen atoms in the side chain, an amino acid having an amino group in the side chain, or an imino group in the side chain. and at least one amino acid selected from the group consisting of an amino acid having a group containing a sulfur atom in its side chain, or at least one amino acid having a pH fine-adjusting action and / or penetrating action.
  • the virucidal agent according to (1) or (2) which is in combination with a nonionic surfactant or a zwitterionic surfactant.
  • the pH adjuster is at least one acidic compound selected from the group consisting of tartaric acid, taurine, glycine, proline, and salts thereof, or the at least one acidic compound and pH fine-adjusting action; / Or the virucidal agent according to (1) or (2), characterized in that it is in combination with a nonionic surfactant or a zwitterionic surfactant having an osmotic action.
  • a virucidal agent comprising a component having a virucidal action and a pH adjuster,
  • the component having virucidal activity comprises at least one selected from the group consisting of silicic acid, silicic acid salts, silicic acid hydrates, sodium hydroxide, calcium hydroxide, and potassium hydroxide
  • the pH adjuster is a resin component, a fiber material, or a combination thereof, the viricidal agent has a pH of less than 12, and the virus is PED virus or SARS-CoV-2 virus. and viricides.
  • a virucidal agent comprising a component having a virucidal action and a pH adjuster
  • the virucidal agent has the form of a urethane resin obtained by combining a component having a virucidal action, a compound having a hydroxyl group, a compound having an isocyanate group, and water as a blowing agent
  • the component having virucidal activity comprises at least one selected from the group consisting of silicic acid, silicic acid salts, silicic acid hydrates, sodium hydroxide, calcium hydroxide, and potassium hydroxide
  • a virucidal agent, wherein the pH adjuster is water, the pH of the virucidal agent is less than 12, and the virus is a PED virus or a SARS-CoV-2 virus.
  • the virucidal agent of the present invention has stable properties, has the effect of inactivating viruses, and is less harmful to humans. This is expected to lead to widespread use of the virucides of the invention, for example in skin, metallic and non-metallic products, natural and synthetic fibres.
  • FIG. 10 is a graph showing test results for PED virus in Example 2.
  • FIG. 10 is a graph showing test results for PED virus in Example 3.
  • FIG. 10 is a graph showing test results against SARS-CoV-2 in Example 4.
  • FIG. 10 is a graph showing test results against SARS-CoV-2 in Example 5.
  • FIG. 10 is a graph showing test results against SARS-CoV-2 in Example 5.
  • One embodiment of the virucidal agent of the present invention comprises a virucidal component and a pH adjuster, wherein the virucidal component is silicic acid, a salt of silicic acid, a hydrate of silicic acid, At least one selected from the group consisting of sodium hydroxide, calcium hydroxide, and potassium hydroxide, and the pH adjuster is a specific acidic compound or a combination of the specific acidic compound and a neutral compound be.
  • the pH adjuster is a specific acidic compound or a combination of the specific acidic compound and a neutral compound be.
  • a pH adjuster can also have for example, even when a pH adjuster is added, it can have an effect equivalent to the virus-inactivating effect that the component having a virucidal action originally has, and the effect can be maintained for a long period of time (for example, 6 months).
  • the pH is less than 12, it is not classified in the GHS (Globally Harmonized System of Classification and Labeling of Chemicals) category, and classified in acute oral toxicity tests in rats, acute skin irritation tests in rabbits, and acute eye irritation tests in rabbits. It is outside and can reduce the harm to humans.
  • GHS Globally Harmonized System of Classification and Labeling of Chemicals
  • the virucidal agent of the present invention can also be used, for example, as a pharmaceutical composition for preventing virus infection.
  • the virucidal agent of the present invention can further contain a resin component and/or a fiber material. That is, the virucidal agent of the present invention includes, for example, a combination of a component having a virucidal action, a pH adjuster and a resin component, a combination of a component having a virucidal action, a pH adjuster and a fiber material, and a virucidal Combinations of active components, pH adjusters, resin components and fiber materials are also included.
  • the pH of the virucidal agent is preferably in the basic range in the GHS division.
  • the lower limit of pH is preferably 10.0 or more, more preferably 11.0 or more, and the upper limit of pH is less than 12. These lower and upper limits can be combined arbitrarily. These combinations can reduce adverse effects on humans.
  • the above pH value is a value measured at 25°C according to the "pH measurement method" in JIS Z-8802:2011.
  • the dosage form of the virucidal agent of the present invention is preferably a liquid or aqueous solution, particularly preferably an aqueous solution.
  • the solvent (water) used for the virucidal agent includes, for example, tap water, soft water, ion-exchanged water, pure water, and purified water.
  • a preferred embodiment of the virucidal agent of the present invention is a virucidal agent comprising silicic acid, a salt of silicic acid, or a hydrate of silicic acid (particularly sodium silicate), a pH adjuster, and water.
  • a virucidal agent consisting of an acid, a salt thereof, or a hydrate thereof (especially sodium silicate), a pH adjuster, a resin component, and water, or a silicic acid, a salt thereof, or a hydrate thereof (especially sodium silicate), a pH adjuster, a fiber material and water, or a silicic acid, a salt thereof, or a hydrate thereof (especially sodium silicate), a pH adjuster and a resin It is a virucidal agent consisting of ingredients, fiber material and water.
  • the virucidal agent of the present invention can be produced according to the common technical knowledge of those skilled in the art.
  • the virucidal agent of the present invention can be prepared by adding a virucidal component, a pH adjuster, a resin component, and/or a fiber material together to a solvent (eg, water) at a stirring speed of 5-80°C. It can be produced by stirring at 10 to 3,000 rpm for 10 to 60 minutes.
  • the ingredient having a virucidal action i.e., an active ingredient as a virucidal agent
  • the ingredient having a virucidal action is selected from the group consisting of silicic acid, salts of silicic acid, hydrates of silicic acid, sodium hydroxide, calcium hydroxide, and potassium hydroxide. At least one selected.
  • the component with virucidal action is preferably silicic acid, a salt of silicic acid or a hydrate of silicic acid.
  • Silicic acid, salts of silicic acid, or hydrates of silicic acid are preferably selected from the group consisting of metasilicic acid, orthosilicic acid, metadisilicic acid, pyrosilicic acid, salts thereof, and hydrates thereof.
  • the metasilicate is preferably at least one compound selected from the group consisting of sodium metasilicate, potassium metasilicate and calcium metasilicate, particularly preferably sodium metasilicate.
  • the component having a virucidal action has a lower limit of preferably 0.01% by mass or more, more preferably 0.05% by mass or more, and even more preferably 0.5% by mass with respect to 100% by mass of the virucidal agent.
  • % or more and its upper limit is 30.0% by mass or less, 5.0% by mass or less, 1% by mass or less, and less than 1% by mass. These lower and upper limits can be combined arbitrarily. Such components and/or numerical ranges can effectively inactivate viruses by a mechanism of action in which the basic aqueous solution dissolves and denatures viral proteins.
  • a high-concentration virucidal component is supplied to the destination, and the high-concentration virucidal component is used as a liquid or aqueous solution at the destination. It can be used by diluting with an agent.
  • pH adjusters include aldehyde group, benzyl group, benzal group, vinyl group, allyl group, ethylene group, methyl group, cetyl group, alkoxy group, methoxy group, ethyl group, propyl group, butyl group, pyridyl group, amyl group, phenylene group, tolyl group, phenyl group, benzoyl group, quinolyl group, naphthyl group, alkyl group, caprine group, lauryl group, myrstyl group, alkylene group, cyano group, carbonyl group, oxalyl group, malonyl group, carboxyl group, nitroso group , at least one acidic compound selected from the group consisting of acidic compounds having at least one group selected from the group consisting of a nitro group, an amino group, an imino group, a hydroxyl group, and a sulfo group, and salts thereof, or
  • the molecular weight of the acidic compound is preferably 50-250 g/mol, more preferably 70-200 g/mol. Molecular weight can be determined, for example, by vapor pressure depression method, boiling point elevation method, freezing point (melting point) depression method (Last method), isothermal distillation method (Buger method), mass spectrometry (FD, FAB method), and functional groups and unsaturated It can be determined by chemometric methods that determine the number of bonds.
  • the acidic compound preferably has 1 to 10, more preferably 3 to 6 carbon atoms.
  • the pH adjuster is preferably at least one acidic compound selected from the group consisting of acidic compounds having a carboxyl group and a hydroxyl group, acidic compounds having a sulfo group, amino acids, and salts thereof, or at least one thereof is a combination of the acidic compound of and the neutral compound.
  • nonionic surfactants examples include nonionic surfactants and zwitterionic surfactants characterized by having pH fine-tuning action and/or penetrating action.
  • Preferred specific examples of nonionic surfactants include higher alcohol nonionic surfactants such as n-octyl- ⁇ -D-glucoside, n-octyl- ⁇ -D-maltoside, n-decyl- ⁇ - D-glucoside, n-decyl- ⁇ -D-maltoside, n-dodecyl- ⁇ -D-glucoside, n-heptyl- ⁇ -D-thioglucoside, n-octyl- ⁇ -D-thioglucoside, n-nonyl- ⁇ -D-thiomaltoside, or poly(oxyethylene) dodecyl ether, poly(oxyethylene) tridecyl ether, poly(oxyethylene) isotridecyl ether, poly(oxyethylene)
  • Examples of acidic compounds having a carboxyl group and a hydroxyl group include tartaric acid, citric acid, lactic acid, or serine.
  • Examples of acidic compounds having a sulfo group include taurine.
  • Examples of amino acids include amino acids having only hydrogen atoms in the side chain (specifically, glycine), amino acids having groups composed of carbon atoms and hydrogen atoms in the side chain (e.g., alanine, valine, leucine, and isoleucine), amino acids with an amide group in the side chain (e.g. asparagine, glutamine), amino acids with an imino group in the side chain (e.g.
  • proline or amino acids with a group containing a sulfur atom in the side chain (e.g. cysteine) is mentioned.
  • Particularly preferred pH adjusters are tartaric acid, taurine, glycine and proline.
  • the above compounds can be used alone or in combination.
  • These acidic compounds and/or combinations of their salts and neutral compounds can be used as pH adjusters.
  • a component having a virucidal action e.g., metasilicic acid
  • a pH adjuster i.e., virucidal properties can be stably maintained.
  • the virucidal action of the virucidal agent cannot be deactivated.
  • the lower limit of the pH adjuster is preferably 0.01% by mass or more, more preferably 0.05% by mass or more, and still more preferably 0.3% by mass or more with respect to 100% by mass of the viricide.
  • There is, and the upper limit is 30.0 mass % or less, 5.0 mass % or less, and 0.7 mass % or less. These lower and upper limits can be combined arbitrarily.
  • the lower limit of the pH adjuster is preferably 0.5 or more, more preferably 0.55 or more, and even more preferably 0.59 or more
  • the upper limit of the pH adjuster is preferably 1.0 Below, it is more preferably 0.9 or less, still more preferably 0.8 or less, particularly preferably 0.7 or less, and particularly preferably 0.64 or less.
  • the mass ratio of the component having virucidal action and the pH adjuster (that is, the component having virucidal action: pH adjuster) is, for example, 1:0.6 to 1 (eg, 0.6, 0.6, 0.6). 8, 0.99, or 1).
  • the pH of the virucidal agent can be made less than 12 by using the above mass ratio.
  • a high-concentration pH adjuster is supplied to a supply destination, and the high-concentration pH adjuster is diluted with an aqueous solution and used at the supply destination. can be done.
  • the virucidal agent and the object to which the virucidal agent is used e.g., the skin of the hands or fingers; , or a combination of tartaric acid and a neutral compound
  • the virucidal agent and the object to which the virucidal agent is used e.g., the skin of the hands or fingers; , or a combination of tartaric acid and a neutral compound
  • water and has a pH of less than 12].
  • resin components include polyester resins, polyvinyl chloride resins, polycarbonate resins, polyethylene terephthalate resins, polyethylene resins, polypropylene resins, polystyrene resins, polyvinyl acetate resins, nylon resins, acrylic resins, alkyd resins, urethane resins, and epoxy resins. , epoxy ester resins, or melamine resins.
  • the resin component is preferably polyester resin, polyvinyl chloride resin, nylon resin, urethane resin or melamine resin, more preferably water-based polyester resin, water-based acrylic resin, water-based urethane resin or water-based melamine resin.
  • Water-based polyester resins, water-based acrylic resins, water-based urethane resins, and water-based melamine resins are water-based polyester resins, water-based acrylic resins, water-based urethane resins, and water-based melamine resins, respectively, dispersed or dissolved in water.
  • the above resins can be used alone or in combination.
  • the lower limit of the resin component is preferably 0.1% by mass or more, more preferably 1.0% by mass or more, and even more preferably 2.0% by mass or more, relative to 100% by mass of the viricide.
  • its upper limit is preferably 10.0% by mass or less, more preferably 8.0% by mass or less, and even more preferably 6.0% by mass or less.
  • the pH of the virucidal agent can be lowered to less than 12 only with the resin component, only the resin component can be used as the pH adjuster. It is also possible to include both a resin component and a pH adjuster in the viricide.
  • a urethane resin as a virucidal agent can be provided by mixing silicic acid, a salt thereof, or a hydrate thereof, a compound having a hydroxyl group, and a compound having an isocyanate group. . That is, it is possible to provide a virucidal agent containing silicic acid, a salt thereof, or a hydrate thereof and a urethane resin, wherein the virucidal agent has a pH of less than 12.
  • silicic acid, its salts or its hydrates for example, silicic acid
  • sodium acid or a combination of the silicic acid, its salts or its hydrates and neutral compounds can be arbitrarily selected and dissolved.
  • the mass of silicic acid, its salts or its hydrates, or the combination of its silicic acid, its salts or its hydrates and its neutral compound is The lower limit is preferably 0.01% by mass or more, more preferably 0.1% by mass or more, and the upper limit is preferably 10.0% by mass or less, more preferably 3.0% by mass or less. is.
  • the compound having a hydroxyl group has a lower limit of preferably 0.01% by mass or more, more preferably 0.05% by mass or more with respect to 100% by mass of the urethane resin as the viricide, and its upper limit is The value is preferably 10.0% by mass or less, more preferably 3.0% by mass or less. These lower and upper limits can be combined arbitrarily.
  • Optional components can be included within the range that does not cause gelation, thickening, and precipitation and does not lose the virucidal effect. In silicic acid, a salt thereof, a hydrate thereof, or a combination thereof with a neutral compound, water is preferred except for the compound having a hydroxyl group, the compound having an isocyanate group, and optional components.
  • a urethane resin can be manufactured according to the common technical knowledge of those skilled in the art.
  • the raw material of urethane resin is supplied to the destination at high concentration, and the raw material of urethane resin with high concentration is diluted with an aqueous solution and used at the destination. can do.
  • the fiber material is preferably a macrofiber material or a nanofiber material, particularly preferably a nanofiber material.
  • Nanofiber materials include, for example, polymer nanofibers, bio-nanofibers, carbon-carbon nanofibers, or nanowires. These nanofiber materials can be used alone or in combination.
  • carboxymethylcellulose nanofibers, cellulose nanofibers, and/or chitin/chitosan nanofibers are preferred, and carboxymethylcellulose nanofibers and/or cellulose nanofibers are particularly preferred.
  • carboxymethylcellulose nanofibers and/or cellulose nanofibers are particularly preferred.
  • the carboxymethylcellulose nanofibers and/or cellulose nanofibers themselves have very high transparency, and furthermore, they contain carboxymethylcellulose nanofibers and/or cellulose nanofibers. This is because the color of the object is not lost when the viricide is coated on the object.
  • the above fiber materials can be used alone or in combination.
  • the lower limit of the fiber material is preferably 0.05% by mass or more, more preferably 0.07% by mass or more, and still more preferably 0.1% by mass or more with respect to 100% by mass of the viricide. and its upper limit is preferably 10.0% by mass or less, more preferably 5.0% by mass or less, and even more preferably 2.0% by mass or less. These lower and upper limits can be combined arbitrarily. These combinations can improve the spreadability of the viricide on organic and inorganic products.
  • the fiber material alone can be used as the pH adjuster. It is also possible to include both a fiber material and a pH adjuster in the viricide.
  • the virucides of the present invention can be used against enveloped or non-enveloped viruses.
  • Enveloped viruses include, for example, SARS-CoV-2, PED virus, or influenza A virus.
  • Non-enveloped viruses include, for example, feline calicivirus.
  • the virucidal agent of the present invention contains a component having a virucidal action, a pH adjuster, a resin component, and a fiber material, as long as the virucidal effect is not lost without causing gelation, viscosity increase, or precipitation. , can contain optional ingredients.
  • a component with virucidal activity e.g., sodium metasilicate
  • a pH adjuster e.g., tartaric acid, or a combination of tartaric acid and a neutral compound
  • water with a pH of less than 12
  • virucidal agent is highly safe for humans and is best suited for inactivating viruses by applying it to the skin of hands or fingers.
  • the viricide is suitable for appliances that are frequently touched by parts of a person (e.g., indoor and outdoor metal or non-metallic doorknobs or handrails; interior and exterior metal or non-metallic doorknobs in cars), and floors, It is also suitable for coating, dip-drying or mixing onto walls, building materials (eg gypsum board) and furniture surfaces.
  • the viricidal agent can be used on natural fibers (such as cotton, linen, silk, or wool), chemical fibers (such as polypropylene, polyethylene, polyester, acrylic, nylon, polyurethane, polyimide, aramid, polymethylpentene, or ethylene). vinyl acetate copolymers), non-woven fabrics, paints, elastomers, adhesives, synthetic leather, foam articles (e.g. foam cushions or insulating foams), or in non-foam articles (e.g. masks, clothing, interior products (eg in furniture or curtains), toys, filters, cushions), coated, dip-dried or mixed.
  • This virucidal agent makes it possible to provide a mask or the like having the function of inactivating viruses.
  • this viricidal agent can be used in gas phase or liquid phase filters and filter media (e.g. activated carbon, zeolite, activated alumina, silica alumina, silica gel, granulated fibers, synthetic aromatic adsorbents, synthetic methacrylate adsorbents). materials, plastic sintered porous bodies, ceramic sintered porous bodies, or glass fibers), coated, dip-dried, or mixed.
  • gas phase or liquid phase filters and filter media e.g. activated carbon, zeolite, activated alumina, silica alumina, silica gel, granulated fibers, synthetic aromatic adsorbents, synthetic methacrylate adsorbents. materials, plastic sintered porous bodies, ceramic sintered porous bodies, or glass fibers), coated, dip-dried, or mixed.
  • a component having a virucidal action e.g., sodium metasilicate
  • a pH adjuster e.g., tartaric acid, or a combination of tartaric acid and a neutral compound
  • a resin component e.g., polyethylene resin
  • water preferably a method for using a virucidal agent having a pH of less than 12
  • the acute oral toxicity test is not classified, and the acute skin irritation test and eye irritation test are non-irritating. That is, it is highly safe for humans.
  • This viricide is suitable for equipment that is frequently touched by human parts (e.g. highly water-repellent metallic or non-metallic doorknobs or handrails), and for floors, walls or furniture surfaces indoors or in premises. Optimal for inactivating viruses by coating.
  • This viricide is highly safe for humans and is ideal for inactivating viruses by applying it to the skin of the hands or fingers.
  • This viricide enhances the adhesion of the viricide by the resin component, so it is recommended that some parts of the equipment that people frequently touch (e.g., metal or non-metal doorknobs or handrails inside and outside the room; inside and outside the car) (metallic or non-metallic doorknobs), or coatings on floors, walls and furniture surfaces.
  • the viricidal agent can be used on natural fibers (such as cotton, linen, silk, or wool), chemical fibers (such as polypropylene, polyethylene, polyester, acrylic, nylon, polyurethane, polyimide, aramid, polymethylpentene, or ethylene). vinyl acetate copolymers), non-woven fabrics, paints, elastomers, adhesives, synthetic leather, foam articles (e.g. foam cushions or insulating foams), or in non-foam articles (e.g. masks, clothing, interior In products (eg furniture or curtains), toys, filters, cushions), coated, dip-dried, or mixed for use.
  • This virucidal agent makes it possible to provide a mask or the like having the function of inactivating viruses.
  • this viricidal agent can be used in gas phase or liquid phase filters and filter media (e.g. activated carbon, zeolite, activated alumina, silica alumina, silica gel, granulated fibers, synthetic aromatic adsorbents, synthetic methacrylate adsorbents). materials, plastic sintered porous bodies, ceramic sintered porous bodies, or glass fibers), coated, dip-dried, or mixed.
  • the use of this viricidal agent can provide gas phase or liquid phase filters and filtration media with the function of inactivating viruses.
  • a component having a virucidal action e.g., sodium metasilicate
  • a pH adjuster e.g., tartaric acid, or a combination of tartaric acid and a neutral compound
  • a fiber material e.g., carboxymethylcellulose nanofiber, chitin/chitosan nanofiber, and/or cellulose nanofiber
  • the virucidal agent contains (preferably consists of) a component having a virucidal action (e.g., sodium metasilicate), a pH adjuster (e.g., tartaric acid), and water, and has a pH of less than 12.
  • a component having a virucidal action e.g., sodium metasilicate
  • a pH adjuster e.g., tartaric acid
  • a resin component e.g., polyethylene resin
  • water preferably from method of using a virucidal agent whose pH is less than 12”.
  • the fiber material preferably, carboxymethyl cellulose nanofiber, chitin/chitosan nanofiber, and/or cellulose nanofiber
  • the fiber material is an aggregate of minute fibers with a width of 3 to 4 nm in which dozens of molecules are bundled. , it has a high surface area (approximately 250 m 2 /g). That is, viricides can be used with extensive deposition of components (silicic acid) that inactivate viruses.
  • this embodiment (virucide with pH less than 12, including silicic acid, pH adjuster, fiber material and water) can be used.
  • Examples 1 to 5 Preparation of viricide
  • Each component was blended in the ratio (unit: mass %) shown in Table 1 below, and these were stirred using a stirrer (manufactured by Tokyo Rika Kikai; small stirrer ZZ-1000S) (Examples 1 to 5: 25 °C, 500 rpm, 60 minutes). This stirring gave the viricides of the present invention (Examples 1-5).
  • Example 1 Evaluation of virucidal action
  • Test Material and Control Material As a test material, the virucidal agent of Example 1 was used as it was. In the evaluation of the virucidal action, the virucidal agent was used after 3 months from the above preparation. On the other hand, a sterilized phosphate buffer (manufactured by Dulbecco; PBS(-)) was used as a control material.
  • Test virus PED virus (Porcine epidemic diarrhea virus P-5V strain; available from Food Environment Laboratory Co., Ltd.) was used as a substitute virus for SARS-CoV-2 virus (commonly known as novel coronavirus).
  • vero cells African green monkey kidney epithelial-derived cells; obtained from Food Environment Research Institute Co., Ltd. were used.
  • Test method The test was performed with reference to "Experimental Virus General Remarks Second Revised Edition Maruzen Co., Ltd. Virus Neutralization Method".
  • test Concentration After serially diluting the test material to 10-fold dilution with phosphate buffer, inoculate it into the cultured cells, confirm the maximum concentration that shows the normal state of the cells after culture, and use the PED virus for the test Concentration was determined.
  • the PED virus addition concentration was set to 10 5 TCID 50/mL or more.
  • Test solution mixing in the main test According to the test section, 1 mL each of the test material and the phosphate buffer was dispensed, and the PED virus solution having the concentration determined in the preliminary test was added.
  • the mixture was allowed to stand at room temperature (25°C) for a predetermined time.
  • 0.1 mL was taken for concentration measurement.
  • 0.1 mL of the virus solution was added again to the remaining test solution, allowed to stand at room temperature for a predetermined time and sensitized by the same method as above, and then the virus solution was added again and the concentration was measured.
  • CPE cytopathic effect
  • the virucidal agent of Example 1 had a virus titer (TCID50: Median Tissue Culture Infectious Dose) one minute after the start of the test. Then it decreased to 75%. Furthermore, TCID50 at 1 minute after re-addition decreased to 84.0%.
  • TCID50 Median Tissue Culture Infectious Dose
  • the TCID50 was 84.0% 1 minute after re-addition (2 minutes after the start of the test).
  • Example 2 (1) Test method Tests were performed with reference to ISO 18184 and ISO 21702.
  • test Material and Control Material A plastic test piece (a square of 5 cm long ⁇ 5 cm wide) was coated with 12 g/m 2 of the virucidal agent of Example 2 and used as a test material. In the evaluation of the virucidal action, the virucidal agent was used after 3 months from the above preparation. On the other hand, an unprocessed plastic test piece (5 cm long x 5 cm wide square) was used as a control material.
  • Test virus PED virus (Porcine epidemic diarrhea virus P-5V strain; source: Food Environment Laboratory Co., Ltd.) was used as a substitute virus for SARS-CoV-2 virus (commonly known as novel coronavirus).
  • vero cells African green monkey kidney epithelium-derived cells; source: Food Environment Research Institute, Inc.
  • Virus solution preparation method PED virus was inoculated into vero cells.
  • B After adsorption at 37° C. for 1 hour, the inoculated virus solution was removed and washed twice with sterile PBS.
  • C MEM medium was added and cultured at 37°C, 5% CO2 .
  • D The culture supernatant was collected when a cytopathic effect (CPE) of about 70 to 80% was observed.
  • CPE cytopathic effect
  • E After centrifuging the recovered culture supernatant at 3000 rpm for 30 minutes, the centrifugation supernatant was dispensed and stored at ⁇ 70° C. or lower to prepare a test virus solution.
  • Test procedure and method (A) Inoculation of virus solution and measurement of virus titer Before starting the test, add 20 mL of cell maintenance medium to the test material and control material to wash out the virus, and Serially diluted 10-fold with cell maintenance medium, each dilution was inoculated into vero cells and cultured for 5 days under 5% CO 2 .
  • vero cells did not show a normal shape, it was determined that the material had cytotoxicity, and the dilution rate at which cytotoxicity was confirmed was excluded from this test.
  • the detection limit for the virus titer per test material was set at 2 ⁇ 10 2.5 TCID50/test piece.
  • the virus titer at the start of the study was 2 ⁇ 10 5.7 (TCID 50 /strip).
  • the virucidal agent of Example 2 did not exhibit the virus-free properties shown in Table 5 and FIG. It has an activating effect. Thus, the virucidal agent of Example 2 has a continuous virus-inactivating effect.
  • Example 3 Virucidal action was evaluated by the same evaluation method as in Example 2, except that the measurement time of the virus titer (TCID 50 ) in Example 2 was changed to "10 minutes after the start of the test".
  • the virus titer at the start of the study was 2 ⁇ 10 5.7 (TCID 50 /strip).
  • the virucidal agent of Example 3 had the virus inactivating effect shown in Table 7 and FIG. have. Thus, the virucidal agent of Example 3 has a continuous virus-inactivating effect.
  • the virus titer (TCID 50 ) for the viricides of Examples 2 and 3 was 2 ⁇ 10 3.9 at 1 minute after the start of the test (i.e., 98.4 % reduction) to 2 x 10 2.5 after 10 minutes (ie, more than 99.9% reduction).
  • Example 4 (1) Test method ISO 18184 (JIS L 1922) was carried out with reference to the antiviral test method for textile products.
  • virus SARS-CoV-2 novel coronavirus * Human-derived isolates: Virus strains that were isolated and cultured from saliva using VERO cells, and then confirmed for amplification of the SARS-CoV-2 gene using real-time PCR (Ministry of Health, Labor and Welfare notification method) Cultured cells: VERO cells (Africa) green monkey kidney epithelium-derived cell line)
  • the detection limit in this test was 10 1.5 TCID 50 /test piece.
  • Judgment was carried out by culturing at 37°C for 5 days in a carbon dioxide gas culture (5%), then observing the cultured cells under a microscope, confirming the presence or absence of virus growth based on CPE (cytopathicity) appearing in the cultured cells, and calculating the concentration. . (d) Evaluation: In the test results, the rate of decrease (%) in the test plot relative to the control plot was calculated for each inspection time point to confirm the effect.
  • Example 5 (1) Test method ISO 18184 (JIS L 1922) Antiviral test method for textile products was used as a reference.
  • Test material A fiber piece coated with a viricide * As a test material, a 2 cm x 2 cm size fiber piece coated with 0.4 g of the viricide of Example 5 was used. *Unprocessed fiber pieces (standard cloth/cotton) were used as control materials.
  • Example 5 The virus titer (TCID 50 ) in Example 5 was evaluated by the same evaluation method as in Example 4 to evaluate the virucidal activity. (3) Establishment of wards

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Le problème décrit par la présente invention est de fournir un agent virucide qui a des propriétés stables, qui présente un effet d'inactivation d'un virus et qui est moins nocif pour les êtres humains. La solution selon l'invention porte sur un agent virucide comprenant un composant virucide et un agent d'ajustement de pH, le composant virucide étant au moins un élément choisi dans le groupe constitué par l'acide silicique, un sel d'acide silicique, l'hydrate d'acide silicique, l'hydroxyde de sodium, l'hydroxyde de calcium et l'hydroxyde de potassium ; l'agent d'ajustement de pH étant un composé acide spécifique éventuellement combiné avec un composé neutre ; et la valeur de pH de l'agent virucide étant inférieure à 12.
PCT/JP2022/018024 2021-05-11 2022-04-18 Agent virucide WO2022239605A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023520939A JPWO2022239605A1 (fr) 2021-05-11 2022-04-18

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-080406 2021-05-11
JP2021080406 2021-05-11

Publications (1)

Publication Number Publication Date
WO2022239605A1 true WO2022239605A1 (fr) 2022-11-17

Family

ID=84029541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/018024 WO2022239605A1 (fr) 2021-05-11 2022-04-18 Agent virucide

Country Status (2)

Country Link
JP (1) JPWO2022239605A1 (fr)
WO (1) WO2022239605A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013082945A (ja) * 2006-01-31 2013-05-09 Tyco Healthcare Group Lp 超柔軟発泡体
JP2014014801A (ja) * 2012-07-11 2014-01-30 Tokyo Univ Of Agriculture & Technology 殺菌水、抗ウィルス剤、生鮮食料品処理システムにおける殺菌用洗浄水並びに養鶏用殺虫剤
WO2014115860A1 (fr) * 2013-01-25 2014-07-31 公立大学法人大阪府立大学 Agent virucide
JP2020125258A (ja) * 2019-02-04 2020-08-20 富士フイルム株式会社 組成物、スプレー、ワイパー

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013082945A (ja) * 2006-01-31 2013-05-09 Tyco Healthcare Group Lp 超柔軟発泡体
JP2014014801A (ja) * 2012-07-11 2014-01-30 Tokyo Univ Of Agriculture & Technology 殺菌水、抗ウィルス剤、生鮮食料品処理システムにおける殺菌用洗浄水並びに養鶏用殺虫剤
WO2014115860A1 (fr) * 2013-01-25 2014-07-31 公立大学法人大阪府立大学 Agent virucide
JP2020125258A (ja) * 2019-02-04 2020-08-20 富士フイルム株式会社 組成物、スプレー、ワイパー

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JANNAT RISAT, DAVID HSU, GARGI MAHESHWARI: "Inactivation of Adenovirus Type 5 by Caustics", BIOTECHNOLOGY PROGRESS, vol. 21, no. 2, 30 April 2005 (2005-04-30), pages 446 - 450, XP093004022, DOI: 10.1021/bp049812f *

Also Published As

Publication number Publication date
JPWO2022239605A1 (fr) 2022-11-17

Similar Documents

Publication Publication Date Title
JP2021138729A (ja) 残留殺菌特性を有する表面殺菌剤
JP5476338B2 (ja) 環状カルボン酸および／または芳香族アルコールを含む過酸化水素殺菌剤
CN100500162C (zh) 抗冠状病毒剂
US4897304A (en) Virucidal composition, the method of use and the product therefor
JP7005492B2 (ja) 残留殺菌特性を有する表面殺菌剤
US11345877B2 (en) Cleaning composition, method of making and use thereof
WO2013012007A1 (fr) Composition d'agent anti-virus
US20230175195A1 (en) Plasma coating treatment method for inhibiting biological pathogen transfer
US11485939B2 (en) Anti-viral cleaning composition, method of making and use thereof
JP2018534331A (ja) 残留殺菌特性を有する表面殺菌剤
WO2022239605A1 (fr) Agent virucide
WO2014115860A1 (fr) Agent virucide
JP2010053091A (ja) 非エンベロープ型ウイルスの不活化剤
CN113749114A (zh) 一种消毒组合物及其方法和用途
JP2020523293A (ja) 残留殺菌特性を有する表面殺菌剤
JP2022015621A (ja) ノロウイルス不活化剤
CN115380915A (zh) 一种消毒组合物及其方法和用途
WO2022075991A1 (fr) Composition de nettoyage antvirale, son procédé de fabrication et son utilisation
WO2023123421A1 (fr) Désinfectant antibactérien à action prolongée, son procédé de préparation et son application
WO2022164466A1 (fr) Compositions antivirales et dispositifs antiviraux et leurs procédés d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22807308

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023520939

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22807308

Country of ref document: EP

Kind code of ref document: A1